药明康德(02359) - 2022 - 年度财报

Financial Performance - In 2022, WuXi AppTec achieved a record revenue growth of 71.8% year-on-year, with total revenue reaching RMB 39,354.8 million compared to RMB 22,902.4 million in 2021[13]. - The adjusted net profit attributable to the parent company increased by 83.2% year-on-year, amounting to RMB 9,399.3 million, up from RMB 5,131.3 million in 2021[13]. - The gross profit margin improved to 36.9% in 2022, compared to 36.1% in the previous year[15]. - The company reported a net profit margin of 22.4% for the parent company, slightly up from 22.3% in 2021[15]. - The company achieved a revenue of RMB 39,354.8 million, representing a year-on-year growth of 71.8%[16]. - The net profit attributable to shareholders reached RMB 8,813.7 million, with a year-on-year increase of 72.9%[16]. - The company reported a net profit of RMB 8,902.6 million for 2022, a 73.3% increase from 2021, with a net profit margin rising from 22.4% to 22.6%[40]. - The company achieved a gross profit of RMB 14,506.5 million in 2022, an increase of 75.5% compared to the same period in 2021, with a main business gross profit of RMB 14,490.8 million and other business gross profit of RMB 15.7 million[26]. - The gross profit margin for the main business was 36.9%, up 0.8 percentage points from 2021[26]. Business Growth and Client Acquisition - WuXi AppTec's CRDMO and CTDMO business models continue to drive growth and meet increasing global customer demands[13]. - The company added over 1,400 new clients, serving more than 5,950 active clients from over 30 countries[16]. - Revenue from US clients was RMB 25,884 million, up 113% year-on-year; revenue from Chinese clients was RMB 7,526 million, up 30%[16]. - The chemical business (WuXi Chemistry) generated RMB 28,849.7 million, a 104.8% increase from RMB 14,087.2 million in 2021[18]. - The TIDES business saw a revenue increase of 337%, reaching RMB 1,578 million, with the number of service molecules growing by 91%[20]. Financial Stability and Assets - Total assets increased to RMB 64,690.3 million in 2022, up from RMB 55,127.4 million in 2021[15]. - The company maintained a debt-to-asset ratio of 27.5%, down from 29.7% in the previous year, indicating improved financial stability[15]. - The company’s cash and cash equivalents stood at RMB 7,983.9 million, compared to RMB 8,175.3 million in 2021[15]. - Total liabilities as of December 31, 2022, were RMB 17,763.7 million, an increase from RMB 16,369.9 million in 2021, with 40.8% attributed to accounts payable and other payables[43]. Research and Development - The company’s R&D expenses rose to RMB 1,614.0 million, a 71.3% increase from 2021, focusing on new molecular types such as PROTAC and gene therapy[35]. - The company aims to enhance its service capabilities for new molecular types such as PROTAC, oligonucleotide drugs, peptide drugs, and gene therapy, capturing new business opportunities[98]. Sustainability and ESG Commitment - The company emphasized its commitment to ESG principles, integrating them into all aspects of its operations[13]. - The company received silver certification from EcoVadis for sustainability ratings across its three bases in Changzhou, Shanghai, and Wuxi[20]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025[120]. Future Outlook and Guidance - For 2023, WuXi Chemistry expects revenue growth of 36-38%, while other segments anticipate a 20-23% increase, with WuXi DDSU projected to decline over 20%[24]. - The company is confident in its future development and maintaining its industry-leading position[13]. - The company expects adjusted non-IFRS gross profit to grow by 12-14% in 2023, contributing to the growth of adjusted non-IFRS profit attributable to equity holders[52]. Corporate Governance and Management - The management team possesses extensive industry experience and a strong international perspective, enabling the company to quickly adapt to market trends and client needs[73]. - The company has established a robust internal control system to ensure compliance with laws and regulations, but risks remain due to the complexity of managing multiple subsidiaries[104]. - The board consists of 13 members, including 6 executive directors, ensuring diverse leadership and strategic oversight[113]. Risks and Challenges - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could negatively impact business if industry trends slow down[101]. - Regulatory changes in the pharmaceutical R&D services industry pose a risk, requiring the company to adapt its strategies to comply with evolving policies[102]. - Increased competition in the global pharmaceutical R&D services market could threaten the company's competitive advantages if it fails to strengthen its R&D capabilities[103]. Shareholder Communication and Dividends - The company has established a shareholder communication policy to ensure proper responses to shareholder concerns and feedback[172]. - The company proposed a cash dividend of RMB 8.9266 per 10 shares for the year 2022, totaling RMB 2,644,137,750.80, compared to RMB 1,529,441,704.14 in 2021[176].